<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 11.3: Cardiovascular Resilience: The Estrogen-Heart Link</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - RED/CRIMSON theme for Cardiovascular Health */
        .module-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #dc2626;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #991b1b;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #fef2f2;
            border: 2px solid #ef4444;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #991b1b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #fee2e2 60%);
            padding: 0 4px;
            font-weight: 500;
            color: #991b1b;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
            letter-spacing: 0.5px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #dc2626, #991b1b);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
            color: white;
        }

        /* Data Table */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f8f9fa;
            padding: 15px;
            font-weight: 600;
            color: #991b1b;
            border-bottom: 2px solid #eee;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #eee;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #991b1b 0%, #dc2626 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
            color: white;
        }

        .stat-highlight {
            font-size: 42px;
            font-weight: 700;
            display: block;
            margin-bottom: 10px;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .reveal-btn {
            background: #991b1b;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #991b1b;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #fef2f2;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* References Box */
        .references-box {
            background: #f9f9f9;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
            font-size: 14px;
            color: #666;
            border: 1px solid #eee;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #333;
            font-size: 16px;
        }

        .references-box ul {
            padding-left: 20px;
            margin: 0;
        }

        .references-box li {
            margin-bottom: 8px;
        }

        /* Takeaways Box */
        .takeaways-box {
            background: #f1f5f9;
            border-left: 5px solid #991b1b;
            padding: 25px;
            margin: 40px 0;
            border-radius: 0 12px 12px 0;
        }

        .takeaways-box h4 {
            margin: 0 0 15px 0;
            color: #991b1b;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
            opacity: 0.9;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 11: Long-Term Vitality & Disease Prevention</p>
            <h1 class="lesson-title">Lesson 11.3: Cardiovascular Resilience: The Estrogen-Heart Link</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 3 of 4</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Window of Opportunity</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Estrogen & Nitric Oxide</a></li>
                <li><a href="#section3"><span class="section-num">3</span>The Lipid Shift & Inflammation</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Tracking HRV & Heart Rate</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Managing Arterial Stiffness</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The THRIVE Heart Protocol</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the "Window of Opportunity" hypothesis and its clinical significance for cardiovascular health.</li>
                <li>Explain the mechanism by which estrogen modulates endothelial function and nitric oxide production.</li>
                <li>Analyze the shift in lipid profiles during the menopause transition and how it links to the "I" (Inflammation Control) pillar.</li>
                <li>Identify non-invasive markers (HRV and RHR) for monitoring autonomic cardiovascular health in the "T" (Track Symptoms) phase.</li>
                <li>Implement evidence-based lifestyle interventions to mitigate menopausal hypertension and arterial stiffness.</li>
            </ul>
        </div>

        <h2 id="section1">1. The 'Window of Opportunity' Hypothesis</h2>
        <p>For decades, the medical community observed a striking phenomenon: pre-menopausal women have significantly lower rates of cardiovascular disease (CVD) compared to men of the same age. However, <span class="highlight">post-menopause, this protection vanishes</span>, and CVD becomes the leading cause of death for women globally.</p>

        <div class="stats-box">
            <span class="stat-highlight">1 in 3</span>
            <p>Women will die from cardiovascular disease, yet only 44% of women recognize that heart disease is their greatest health threat. Post-menopause, a woman's risk of heart attack increases by nearly 300% within 10 years of the final menstrual period.</p>
        </div>

        <p>The "Window of Opportunity" hypothesis suggests that the cardiovascular benefits of estrogen (and Menopause Hormone Therapy, or MHT) are highly dependent on <strong>timing</strong>. Initiating supportâ€”whether through lifestyle or hormonesâ€”during perimenopause or the early post-menopausal years (within 10 years of the final period) appears to protect the vascular endothelium. Conversely, starting MHT too late, when atherosclerosis is already established, may actually increase risk. As a Menopause Support Coach, your role is to help clients maximize this window through the <strong>THRIVE Methodologyâ„¢</strong>.</p>

        <h2 id="section2">2. Endothelial Function and Nitric Oxide</h2>
        <p>The endothelium is the thin layer of cells lining our blood vessels. It is not merely a barrier; it is a dynamic endocrine organ. Estrogen acts as a master regulator of this system by stimulating the enzyme <span class="highlight">eNOS (endothelial nitric oxide synthase)</span>.</p>

        <p><strong>The Nitric Oxide Mechanism:</strong>
            <br>1. Estrogen binds to receptors on the blood vessel walls.
            <br>2. This triggers the production of <strong>Nitric Oxide (NO)</strong>.
            <br>3. NO promotes <strong>vasodilation</strong> (opening of the vessels), prevents blood clots, and reduces the "stickiness" of the vessel walls that leads to plaque buildup.
        </p>

        <p>When estrogen levels plummet, NO production drops. This leads to <span class="highlight">Endothelial Dysfunction</span>â€”the vessels become stiffer, less responsive to blood flow changes, and more prone to the inflammatory damage we discussed in Module 4.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The 'Sudden' Hypertension</p>
                    <p style="color:white; font-size:12px; margin:0;">Client: Elena, Age 52, Late Perimenopause</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena, 52</h4>
                        <p>Presenting: Increasing BP (145/92), frequent palpitations, and "internal heat" not related to hot flashes.</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Using the <strong>"T" (Track Symptoms)</strong> pillar, Elena tracked her BP alongside her cycle. We noted her BP spiked during her luteal phase when estrogen was most volatile. Under the <strong>"I" (Inflammation Control)</strong> pillar, we introduced high-nitrate foods (arugula, beets) and L-citrulline to support NO production.</p>
                <p><strong>Outcome:</strong> After 12 weeks of NO-supportive nutrition and daily zone 2 cardio, her resting BP stabilized at 128/84. Her physician was able to delay medication, opting for continued lifestyle monitoring.</p>
            </div>
        </div>

        <h2 id="section3">3. Lipid Profile Shifts: The 'I' Pillar Connection</h2>
        <p>The menopausal transition is associated with a pro-atherogenic shift in lipids. This isn't just about "eating too much fat"â€”it's a metabolic reprogramming caused by the loss of estrogen's influence on the liver and adipose tissue.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>Pre-Menopause Trend</th>
                        <th>Post-Menopause Shift</th>
                        <th>Impact on Risk</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>LDL (Bad Cholesterol)</td>
                        <td>Lower, larger particles</td>
                        <td>Increased (up to 15-20%)</td>
                        <td>Higher plaque formation</td>
                    </tr>
                    <tr>
                        <td>HDL (Good Cholesterol)</td>
                        <td>Higher, cardioprotective</td>
                        <td>Decreased or less functional</td>
                        <td>Reduced reverse lipid transport</td>
                    </tr>
                    <tr>
                        <td>Triglycerides</td>
                        <td>Regulated by estrogen</td>
                        <td>Significant increase</td>
                        <td>Linked to insulin resistance</td>
                    </tr>
                    <tr>
                        <td>Lp(a)</td>
                        <td>Stable</td>
                        <td>Can increase by 10-15%</td>
                        <td>Genetic risk multiplier</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <p>This shift directly links to the <strong>"I" (Inflammation Control)</strong> pillar. Elevated LDL is most dangerous when it becomes <strong>oxidized</strong>. Without the anti-inflammatory shield of estrogen (Module 4), LDL is more easily oxidized, triggering the immune system to create foam cells and arterial plaque.</p>

        <h2 id="section4">4. Non-Invasive Markers: Monitoring HRV and RHR</h2>
        <p>In the <strong>"T" (Track Symptoms)</strong> phase of the THRIVE Method, we move beyond just tracking hot flashes to tracking autonomic cardiovascular health. Two key metrics are <span class="highlight">Heart Rate Variability (HRV)</span> and <span class="highlight">Resting Heart Rate (RHR)</span>.</p>

        <p><strong>Heart Rate Variability (HRV):</strong>
            <br>HRV measures the variation in time between each heartbeat. A high HRV indicates a resilient autonomic nervous system. Research shows that as women transition through menopause, HRV typically <strong>decreases</strong>, signaling a shift toward "sympathetic dominance" (fight or flight).
        </p>

        <p><strong>Resting Heart Rate (RHR):</strong>
            <br>An increasing RHR in midlife can be an early warning sign of declining cardiovascular fitness and increasing arterial stiffness. A 2021 study found that women whose RHR increased by more than 5 bpm during the transition had a 12% higher risk of CVD events.</p>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Tip</p>
            <p>Encourage clients to use wearable tech (Oura, Whoop, Apple Watch) not just for steps, but to monitor their <strong>7-day HRV average</strong>. A sudden drop in the weekly baseline often precedes a symptomatic flare-up or indicates the need for more "R" (Reset Metabolism) recovery work.</p>
        </div>

        <h2 id="section5">5. Managing Menopausal Hypertension & Arterial Stiffness</h2>
        <p>Menopausal hypertension is often "salt-sensitive" and driven by the <span class="highlight">Renin-Angiotensin-Aldosterone System (RAAS)</span>, which estrogen normally helps keep in check. When estrogen declines, the body becomes more sensitive to salt, and blood vessels lose their elasticity.</p>

        <p><strong>Arterial Stiffness</strong> (measured clinically by Pulse Wave Velocity) is a hallmark of the post-menopausal state. It increases the workload on the heart, leading to Left Ventricular Hypertrophy (thickening of the heart muscle). To combat this, we focus on:</p>
        <ul>
            <li><strong>Magnesium Loading:</strong> Magnesium acts as a natural calcium channel blocker, helping smooth muscle in the arteries relax.</li>
            <li><strong>Potassium/Sodium Ratio:</strong> Increasing potassium (avocados, spinach, beans) to counteract salt sensitivity.</li>
            <li><strong>Isometric Exercise:</strong> Research suggests isometric wall sits can be as effective as aerobic exercise for lowering systolic BP in women.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The Athlete's Decline</p>
                    <p style="color:white; font-size:12px; margin:0;">Client: Sarah, Age 55, Post-Menopause</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, 55</h4>
                        <p>Profile: Marathon runner, low body fat, but suddenly experiencing high LDL and stiffening of the arteries (confirmed by calcium score).</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Sarah was over-training, causing high cortisol which exacerbated her arterial stiffness. We used <strong>"H" (Hormone Harmony)</strong> to balance her HPA-axis and shifted her to <strong>"R" (Reset Metabolism)</strong> focused strength training instead of chronic cardio. We also added 2g of Omega-3 (EPA/DHA) to improve her Omega-3 index.</p>
                <p><strong>Outcome:</strong> Her HRV baseline increased from 22ms to 38ms over 4 months, and her arterial compliance improved, noted by her cardiologist during a follow-up stress test.</p>
            </div>
        </div>

        <h2 id="section6">6. The THRIVE Heart Protocol</h2>
        <p>As we integrate these findings into our coaching, the <strong>THRIVE Methodologyâ„¢</strong> provides a structured path for cardiovascular resilience:</p>

        <div class="principle-card">
            <div class="principle-title">T: Track (The Early Warning System)</div>
            <p class="principle-text">Monitor BP twice weekly; track HRV/RHR trends; record palpitations in relation to caffeine, alcohol, and stress.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">H: Hormone Harmony (The Foundation)</div>
            <p class="principle-text">Support the "Window of Opportunity." If a client is a candidate for MHT, ensure they discuss transdermal options with their doctor, as these carry lower thrombotic (clot) risk.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">R: Reset Metabolism (The Engine)</div>
            <p class="principle-text">Focus on insulin sensitivity. Insulin resistance is a major driver of endothelial damage. Prioritize muscle mass to act as a glucose sink.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">I: Inflammation Control (The Shield)</div>
            <p class="principle-text">Use the "Anti-Inflammatory Kitchen" (Module 4) to prevent LDL oxidation. High-fiber intake (35g+) to clear excess cholesterol via the Estrobolome (Module 11, L1).</p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of the Estrogen-Heart link.</p>

            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why is the "Window of Opportunity" so critical for cardiovascular health in menopause?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">The "Window of Opportunity" (typically within 10 years of the final period) is when the vascular endothelium is still responsive to estrogen's protective effects. After this window, atherosclerosis may be too advanced, and starting MHT could potentially increase the risk of plaque rupture.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">What is the primary mechanism by which estrogen keeps arteries flexible and "non-stick"?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Estrogen stimulates the production of Nitric Oxide (NO) via the eNOS enzyme. Nitric Oxide promotes vasodilation, inhibits platelet aggregation (clotting), and prevents inflammatory cells from sticking to the vessel walls.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <h4>Lesson Key Takeaways</h4>
            <ul>
                <li><strong>Heart Disease is the #1 Killer:</strong> Menopause is a cardiovascular "pivot point" where risk escalates rapidly due to estrogen loss.</li>
                <li><strong>Nitric Oxide is the Key:</strong> Declining estrogen leads to endothelial dysfunction and reduced NO, causing arterial stiffness.</li>
                <li><strong>Lipids Shift Metabolically:</strong> The rise in LDL and triglycerides post-menopause requires aggressive "I" (Inflammation Control) to prevent plaque formation.</li>
                <li><strong>Track the Autonomic System:</strong> HRV and RHR are vital non-invasive markers for monitoring the cardiovascular transition.</li>
                <li><strong>Timing Matters:</strong> Intervening early in the transition (The Window of Opportunity) provides the greatest long-term protection.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Manson, J.E., et al. (2013). "Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Womenâ€™s Health Initiative Randomized Trials." JAMA.</li>
                <li>El Khoudary, S.R., et al. (2020). "Menopause Transition and Cardiovascular Disease Risk: Implications for Contemporary Management." Circulation (American Heart Association).</li>
                <li>Rossouw, J.E., et al. (2007). "Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause." JAMA.</li>
                <li>Samargandy, S., et al. (2021). "Arterial Stiffness Accelerates Within 1 Year of the Final Menstrual Period: The SWAN Heart Study." Arteriosclerosis, Thrombosis, and Vascular Biology.</li>
                <li>Naftolin, F., et al. (2019). "Cardiovascular Health and the Menopausal Woman: The Role of Estrogen and Progesterone." Menopause Journal.</li>
                <li>Vlachopoulos, C., et al. (2015). "Aortic Stiffness and Cardiovascular Risk in Women: The Role of Menopause." Hypertension.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Menopause Support Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. The T.H.R.I.V.E. Methodologyâ„¢ is a proprietary framework.</p>
        </footer>
    </div>
</body>

</html>